Kurt Hilzinger - Humana Independent Chairman of the Board
HUM Etf | USD 296.68 0.00 0.00% |
Mr. Kurt J. Hilzinger is the Independent Chairman of the Board of Humana Inc. Mr. Hilzinger was initially elected to the Board in July 2003, and was elected Chairman of the Board effective January 1, 2014. Mr. Hilzinger served as Lead Director from August 2010 until his appointment as Chairman. Mr. Hilzinger is a Partner at Court Square Capital Partners, an independent private equity firm, having held this position since November 2007. Prior to that, he was a Director of AmerisourceBergen Corporation from March 2004 to November 2007 having previously served as President and Chief Operating Officer of AmerisourceBergen Corporation from October 2002 to November 2007, and as Executive Vice President and Chief Operating Officer from August 2001 to October 2002
Age | 60 |
Tenure | 10 years |
Address | Humana Building, Louisville, KY, United States, 40202 |
Phone | 502 580 1000 |
Web | https://www.humana.com |
Humana Management Efficiency
The company has Return on Asset of 0.0401 % which means that on every $100 spent on assets, it made $0.0401 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0784 %, implying that it generated $0.0784 on every 100 dollars invested. Humana's management efficiency ratios could be used to measure how well Humana manages its routine affairs as well as how well it operates its assets and liabilities.Similar Fund Executives
Found 7 records | One Year Return | ||
Richard Burke | UnitedHealth Group Incorporated | 76 | |
Isaiah Harris | Cigna Corp | 68 | |
Stephen Hemsley | UnitedHealth Group Incorporated | 67 | |
David Dorman | CVS Health Corp | 66 | |
H Dallas | Centene Corp | 62 | |
Michael Neidorff | Centene Corp | 81 | |
Ronna Romney | Molina Healthcare | 77 |
Management Performance
Return On Equity | 0.0784 | ||||
Return On Asset | 0.0401 |
Humana Inc Money Managers
David Jones, Independent Director | ||
Kurt Hilzinger, Independent Chairman of the Board | ||
Joseph Ventura, Chief Legal Officer and Corporate Secretary | ||
Vishal MD, Chief Officer | ||
Susan Schick, Segment President Group and Military Business | ||
Raquel Bono, Independent Director | ||
Jorge Mesquita, Independent Director | ||
W Dunbar, Independent Director | ||
David Feinberg, Independent Director | ||
Cynthia Zipperle, Senior Vice President, Chief Accounting Officer, Controller | ||
Heather Carroll, Chief Digital Health and Analytics Officer | ||
Marissa Peterson, Independent Director | ||
Alan Wheatley, Segment President - Retail | ||
James MBA, President COO | ||
Kate Goodrich, Senior Officer | ||
Timothy Wheatley, Segment Retail | ||
Christopher Hunter, Segment President, Group and Military Business | ||
Susan Diamond, Chief Financial Officer, Segment President, Home Business | ||
Andrew Agwunobi, President - Home Solutions Business | ||
Heather Cox, Chief Digital Health and Analytics Officer | ||
Jessica Clark, Senior Improvement | ||
David Dintenfass, President Growth | ||
Jennifer Bazante, Chief Marketing Officer | ||
James OBrien, Independent Director | ||
Amy Fry, Sr Communications | ||
John III, Senior President | ||
Marcy Klevorn, Independent Director | ||
Nwando Olayiwola, Senior Vice President Chief Health Equity Officer | ||
William Fleming, Segment President, Pharmacy Solutions and Chief Corporate Affairs Officer | ||
Vishal Agrawal, Chief Strategy and Corporate Development Officer | ||
Brian Kane, Chief Financial Officer | ||
Wayne Frederick, Independent Director | ||
PharmD PharmD, Chief Solutions | ||
Bethanie Stein, President Pharmacy | ||
Frank DAmelio, Independent Director | ||
Erin Champlin, Senior Experience | ||
Timothy Huval, Chief Human Resource Officer, Chief Administrative Officer | ||
Sue Schick, President - Military and Specialty Businesses | ||
T Wheatley, Segment President - Retail | ||
Tracy Nolan, Senior MarketPoint | ||
Sam Deshpande, Chief Technology Officer, Chief Risk Officer | ||
Bruce Broussard, CEO and President Director and Chairman of Executive Committee | ||
George II, President Medicaid | ||
Eric Tagliere, Senior CTO | ||
Frank Bisignano, Independent Director | ||
Samir Deshpande, Chief Information Officer | ||
William Shrank, Chief Medical and Corporate Affairs Officer | ||
John Garratt, Independent Director | ||
MD MBA, President CenterWell | ||
Carolyn Tandy, Senior Vice President and Chief Inclusion and Diversity Officer | ||
Jay Khosla, Senior Officer | ||
William McDonald, Independent Director | ||
JohnPaul Felter, Chief VP | ||
Lisa Stoner, Vice Relations | ||
Michael Koeberlein, Senior Vice President Chief Accounting Officer, Controller | ||
Karen Katz, Independent Director |
Humana Etf Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Humana a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0784 | ||||
Return On Asset | 0.0401 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.03 % | ||||
Current Valuation | 44.53 B | ||||
Shares Outstanding | 120.41 M | ||||
Shares Owned By Insiders | 0.21 % | ||||
Shares Owned By Institutions | 94.75 % | ||||
Number Of Shares Shorted | 4.38 M | ||||
Price To Earning | 19.12 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Humana Etf
Humana financial ratios help investors to determine whether Humana Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Humana with respect to the benefits of owning Humana security.